ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos792.2 M633 M634.2 M657.8 M775 M2.7 BInvestigación y desarrollo1.41 B1.33 B1.42 B1.48 B1.63 B5.85 BBeneficio operativo990.2 M591.7 M1.08 B1.03 B879.9 M3.58 BTotal de ingresos no operativos-32.1 M313.3 M439.2 M736.5 M163.8 M1.65 BGastos por intereses, netos de intereses capitalizados10.5 M8.7 M3.6 M19.3 M12.2 M43.8 MIngresos no operativos, una vez deducidos los gastos por intereses-21 M-17.4 M-7.2 M-38.6 M-24.4 M-87.6 MIngresos/gastos extraordinarios-21.6 M322 M442.8 M755.8 M176 M1.7 BBeneficio antes de impuestos958.1 M905 M1.52 B1.76 B1.04 B5.23 BParticipación en los beneficios——————Impuestos40.4 M96.3 M127.1 M303.3 M199.1 M725.8 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos-55.4 M-3.2 M20.9 M-16.3 M-136.9 M-135.5 MBeneficio neto antes de actividades interrumpidas917.7 M808.7 M1.39 B1.46 B844.6 M4.5 BOperaciones suspendidas——————Beneficio neto917.7 M808.7 M1.39 B1.46 B844.6 M4.5 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas917.7 M808.7 M1.39 B1.46 B844.6 M4.5 BBeneficio básico por acción8.557.5813.2414.098.1643.07Beneficio por acción diluido8.127.2712.8113.627.7841.48Número medio de acciones ordinarias107.9 M106.7 M105.1 M103.6 M104.6 M420 MAcciones diluidas115.1 M111.2 M108.6 M107.2 M108.6 M435.6 MEBITDA1.12 B718.6 M1.21 B1.16 B1.02 B4.12 BEBIT990.2 M591.7 M1.08 B1.03 B879.9 M3.58 BCosto de los ingresos——————Otros costes de producción——————Amortización y depreciación (flujo de caja)126.4 M126.9 M135.1 M136.7 M145 M543.7 M
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.